We're not talking about tasigna and it doesn't have more side effects than omecataxine. Injection, i.v., whatever. It's inconvenient in a market that's entirely oral. My pessimism is easy to understand. This is chemotherapy and has a high degree of grade 3/4 tox. It's not specific. The efficacy is unimpressive. It has a short duration. Approval is no lock imo. Its only hope is that it's a salvage option albeit a weak one. But even with approval, this thing is D.O.A. in CML before it's even approved.
<<to avoid relapses you would give yourself a shot. it isn't IV.>>>
I would enroll in a clinical trial instead. Omecataxine would be like putting a wet bandaid on it won't last long.
<<and you said 10 percent cytogenic response is not impressive, but these are after other drugs failed. Earlier in the process, or in combo they would get higher responses.>>>
10% is terrible. yes. Any chemo will do the same. Omecataxine will never be used in front line if that's what you're driving at and combo's would be useless and very toxic for the patient.
Either way this is fairly pointless to keep discussing. Wait until the briefing documents come out and or tepid commercial sales and that will speak for me.
Market Data 
Markets 
AI
